Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDROMEDA: Radiation + Systemic Therapy vs Systemic Therapy Alone in Oligometastatic NSCLC
NCT06141070Phase 3Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Dec 2023
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Overall Survival at 60 months. Started Dec 2023; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06141070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141070.